. 2015 Apr 13;36(5):614–626. doi: 10.1038/aps.2015.4

Table 1. IC₅₀ values of erlotinib or amiloride, and the mutation status of EGFR and K-Ras genes in human pancreatic cancer cell lines.

Cell line	EGFR genotype	K-Ras genotype	IC₅₀ of erlotinib (μmol/L, mean±SD)	IC₅₀ of amiloride (μmol/L, mean±SD)
Bxpc-3	WT	WT	224.4±16.5	151.7±3.8
PANC-1	WT	G12D	68.1±2.4	216.7±16.2
Aspc-1	WT	G12D	103.7±8.8	283.9±26.1
CFPAC-1	WT	G12V	125.8±7.3	188.3±17.9

WT: wild type; the mutation status of the EGFR or K-Ras genes was obtained from www.sanger.ac.uk; IC₅₀ values were determined by MTT assay after 48 h treatment and calculated using nonlinear regression by GraphPad Prism 3.0, each value represents the mean±SD from at least three independent experiments.

Table 1. IC50 values of erlotinib or amiloride, and the mutation status of EGFR and K-Ras genes in human pancreatic cancer cell lines.

Table 1. IC₅₀ values of erlotinib or amiloride, and the mutation status of EGFR and K-Ras genes in human pancreatic cancer cell lines.